Home・Список акций・Bio-Techne Corp

Bio-Techne Corp

Закрыт

СекторЗдравоохранение

72.33 0.03

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

72.25

Макс.

72.34

Ключевые показатели
By Trading Economics
Доход	3.6M 55M
Продажи	9.8M 321M
P/E Средняя по отрасли	62.405 57.371
Прибыль на акцию	0.49
Дивидендная доходность	0.44
Рентабельность продаж	17.006
Сотрудники	3,000
EBITDA	-6.7M 92M

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	-0.24% downside

Дивиденды
By Acuity
Дивидендная доходность Средняя по отрасли	0.44% 2.23%
Следующий отчет о доходах	4 нояб. 2026 г.
Дата следующей выплаты дивидендов	28 авг. 2026 г.
Следующая эксдивидендная дата	24 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	42M 11B
Предыдущая цена открытия	72.3
Предыдущая цена закрытия	72.33

Новостные настроения

By Acuity

50%

171 / 340 Рейтинг в Healthcare

Bio-Techne Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

19 авг. 2026 г., 19:27 UTC

Correlated Moves

Shares modestly higher, influenced by rise in iShares Biotechnology ETF.

18 авг. 2026 г., 21:41 UTC

Bio-Techne Corp shares are higher in after-market trading, peaking early in the session and remaining near the upper end of their one-month trading range.

17 авг. 2026 г., 19:16 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat amid broader market sentiment, with the Russell 2000 Index declining. Recent economic data has contributed to cautious conditions.

13 авг. 2026 г., 19:16 UTC

Correlated Moves

News

Bio-Techne Corp corrected its dividend record date to August 24, 2026. Shares are trading roughly flat amid broader market dynamics.

5 авг. 2026 г., 19:16 UTC

Correlated Moves

Bio-Techne Corp's shares are lower today, reflecting declines in the Russell 2000 Index. The stock remains near the upper end of its one-month trading range.

4 авг. 2026 г., 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are higher in after-market trading, buoyed by positive sentiment from U.S.-Iran negotiations and gains in major technology stocks.

3 авг. 2026 г., 19:26 UTC

Correlated Moves

Bio-Techne Corp is advancing, reflecting broader market positivity amid gains in major tech stocks and falling energy prices. The stock is near its one-month trading range high.

31 июл. 2026 г., 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are lower in after-market trading amid a broader market downturn, reflecting negative sentiment impacting price action.

30 июл. 2026 г., 18:26 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat as the broader market recovers from declines, influenced by rising Treasury yields and inflation concerns.

29 июл. 2026 г., 22:03 UTC

Bio-Techne Corp shares are lower in after-market hours, reflecting a decline since Wednesday's close amid cautious market sentiment and geopolitical tensions.

20 июл. 2026 г., 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Сравнение c конкурентами

Изменение цены

Bio-Techne Corp Прогноз

Целевая цена

By TipRanks

-0.24% падение

Прогноз на 12 месяцев

Средняя 72.11 USD -0.24%

Максимум 73 USD

Минимум 65 USD

Основано на мнении 11 аналитиков Wall Street, спрогнозировавших целевые цены для Bio-Techne Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

11 ratings

Покупка

Удержание

Продажа

Основано на мнении 11 аналитиков, присваивавших рейтинги акциям Bio-Techne Corp – Данные за последние 3 месяца.

Настроения

By Acuity

171 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.